NASDAQ:INBX 24 October 2025

Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News

Inhibrx’s ozekibart cut risk of progression or death by 52% in Phase 2 chondrosarcoma trial, doubling median progression-free survival to 5.52 months versus placebo. Shares of INBX jumped about 70% intraday and closed at $28.36 on Oct. 23, then surged another 75–80% after hours. Management plans a BLA filing in Q2 2026. Ozekibart also showed high response rates in colorectal and Ewing sarcoma cohorts.

24 October 2025

Biotechnology·NASDAQ:INBX·Stock Market

Evertz Technologies Fair Value Targets Lifted by Analysts on TSX
March 20, 2026, 2:37 PM EDT. Analysts have raised the fair value estimate for Evertz Technologies (TSX:ET) from CA$14.88 to CA$17.25, reflecting a roughly 16% increase and aligning with a cluster of price targets between CA$16 and CA$17.50. Canaccord and BMO Capital have each lifted their price targets to CA$17.50, maintaining positive ratings, while RBC Capital has raised its target incrementally to CA$16 but retains a cautious Sector Perform stance. The upward revisions follow updated assumptions, including a slight dip in revenue growth to 4.16% and an improved net profit margin to 12.98%. The stock's quarterly dividend was declared at CA$0.2050 per share, payable March 2026. Investors should note the narrowed upside range and potential risks flagged, advising careful consideration of entry points and expectations.